Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Bullboard Posts
Comment by Riverfolkon Apr 30, 2020 10:24am
49 Views
Post# 30970962

RE:COVID 19 - GOV GRANTS FOR TREATMENT

RE:COVID 19 - GOV GRANTS FOR TREATMENT

In Canada there is only a handful of companies that have any potential treatment for COVID. Most companies hopped on the bandwagon when the pandemic started and have to begin the process from the ground floor. Arch has been developing their drug library for LUNG, KIDNEY and LIVER for years, Timing is definitely in their favour as they had completed thier Expanded phase 1 in Australia in the early pandemic months. Here is why I believe they will receive government grants:

- Look at the Arch board and Advisors, this group has a history of credible science
- Arch has a ready to use drug manufactured from phase one, proven safe for humans.  I am unsure about remaining quantities though
- Made in Canada story 
- THE ONLY DRUG IN THE WORLD THAT TREATS TWO ORGANS COVID 19 ATTACKS, the kidney and lung.
- Post COVID 19, is this drug in Canada could start a needed industry in province for years.
- The treatment for the liver could offset effects from other covid drugs used also.

Remember that without covid, Metablok was the only KIDNEY treatment for inflammation in the world with a market of 100 million patients annually. 

I invested in the Science
 

Bullboard Posts